Microtubules as antifungal and antiparasitic drug targets

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 2, 2011, Pages 167-186

  Chatterji, Biswa Prasun ^a   Jindal, Bhavya ^a   Srivastava, Sanjeeva ^a   Panda, Dulal ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

Anthelminthic; anticancer drugs; antifungal; antiprotozoan; microtubules; recombinant tubulin; RNAi; tubulin; tubulin targeting drugs; vaccine

Indexed keywords

ALBENDAZOLE; ANTIFUNGAL AGENT; ANTIPARASITIC AGENT; BENZIMIDAZOLE; DOCETAXEL; DOUBLE STRANDED RNA; FLUBENDAZOLE; MEBENDAZOLE; OXIBENDAZOLE; TIABENDAZOLE; TRICLABENDAZOLE; TRIFLURALIN;

ANIMAL PARASITOSIS; ANTIFUNGAL ACTIVITY; APICOMPLEXA; CANDIDA ALBICANS; COCCIDIA; DRUG TARGETING; GIARDIA; IMMUNE RESPONSE; KINETOPLASTIDA; MAMMAL; MICROTUBULE; NONHUMAN; PLASMODIUM; PROTOZOON; REVIEW; RNA INTERFERENCE; VACCINATION;

ANIMALS; ANTIFUNGAL AGENTS; ANTIPARASITIC AGENTS; HUMANS; MICROTUBULES; PATENTS AS TOPIC; TUBULIN MODULATORS;

EID: 79952910117     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.545349     Document Type: Review

References (160)

1. Pink R, Hudson A, Mouries MA, Bendig M. Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov 2005;4:727-40 A general review on advances of drug discovery in parasitic diseases. (Pubitemid 43090494)
2. Odds FC. Editorial: Resistance to antifungal agents. Fungal Genet Biol 2010;47:190
3. Renslo AR, McKerrow JH. Drug discovery and development for neglected parasitic diseases. Nat Chem Biol 2006;2:701-10 (Pubitemid 44764212)
4. Bell A. Microtubule inhibitors as potential antimalarial agents. Parasitol Today 1998;14:234-40 (Pubitemid 28240080)
5. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65 A general review on microtubule-targeting drugs. (Pubitemid 38525281)
6. Carlson RO. New tubulin targeting agents currently in clinical development. Expert Opin Investig Drugs 2008;17:707-22 (Pubitemid 351843615)
7. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000;16:89-111 A general review on drug binding sites on tubulin. (Pubitemid 32037501)
8. Robinson MW, McFerran N, Trudgett A, et al A possible model of benzimidazole binding to beta-tubulin disclosed by invoking an inter-domain movement. J Mol Graph Model 2004;23:275-84 (Pubitemid 39463106)
9. Nyporko AY, Yemets AI, Brytsun VN, et al Structural and biological characterization of the tubulin interaction with dinitroanilines. Cytol Genet 2009;43:267-82
10. Rathinasamy K, Jindal B, Asthana J, et al Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine. BMC Cancer 2010;10:213
11. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol 1988;18:885-936 . An excellent review on microtubule-targeting anthelminthics. (Pubitemid 19001491)
12. Davidse LC. Benzimidazole fungicides: Mechanism of action and biological impact. Ann Rev Phytopathol 1986;24:43-65
13. Chan MM, Fong D. Plant microtubule inhibitors against trypanosomatids. Parasitol Today 1994;10:448-51 (Pubitemid 24321981)
14. Werbovetz KA. Tubulin as an antiprotozoal drug target. Mini Rev Med Chem 2002;2:519-29
15. Anthony RG, Hussey PJ. Dinitroaniline herbicide resistance and the microtubule cytoskeleton. Trends Plant Sci 1999;4:112-16 (Pubitemid 29141598)
16. Chan MM, Triemer RE, Fong D. Effect of the anti-microtubule drug oryzalin on growth and differentiation of the parasitic protozoan Leishmania mexicana. Differentiation 1991;46:15-21
17. Chan MM, Fong D. Inhibition of leishmanias but not host macrophages by the antitubulin herbicide trifluralin. Science 1990;249:924-6
18. Keeling PJ, Doolittle WF. Alpha-tubulin from early-diverging eukaryotic lineages and the evolution of the tubulin family. Mol Biol Evol 1996;13:1297-305 Similarities and dissimilarities of parasite, fungal and mammalian tubulin sequences are discussed in this article. (Pubitemid 26408935)
19. Edlind TD, Li J, Visvesvara GS, et al Phylogenetic analysis of beta-tubulin sequences from amitochondrial protozoa. Mol Phylogenet Evol 1996;5:359-67 (Pubitemid 126321176)
20. Wesseling JG, Dirks R, Smits MA, Schoenmakers JG. Nucleotide sequence and expression of a beta-tubulin gene from Plasmodium falciparum, a malarial parasite of man. Gene 1989;83:301-9 (Pubitemid 20001137)
21. Morejohn LC, Fosket DE. The biochemistry of compounds with anti-microtubule activity in plant cells. Pharmacol Ther 1991;51:217-30
22. Gull K. The cytoskeleton of trypanosomatid parasites. Annu Rev Microbiol 1999;53:629-55 (Pubitemid 29503743)
23. Santos JM, Lebrun M, Daher W, et al Apicomplexan cytoskeleton and motors: Key regulators in morphogenesis, cell division, transport and motility. Int J Parasitol 2009;39:153-62
24. Pinder J, Fowler R, Bannister L, et al Motile systems in malaria merozoites: How is the red blood cell invaded? Parasitol Today 2000;16:240-5 (Pubitemid 30332126)
25. Fowler RE, Fookes RE, Lavin F, et al Microtubules in Plasmodium falciparum merozoites and their importance for invasion of erythrocytes. Parasitology 1998;117:425-33 (Pubitemid 28505765)
26. Bejon PA, Bannister LH, Fowler RE, et al A role for microtubules in Plasmodium falciparum merozoite invasion. Parasitology 1997;114:1-6 (Pubitemid 27022697)
27. Fennell BJ, Naughton JA, Barlow J, et al Microtubules as antiparasitic drug targets. Expert Opin Drug Discov 2008;3:501-18 . A review article describing existing and promising tubulin-targeting compounds to treat parasitic illnesses. (Pubitemid 351771991)
28. Sheehy TW, Reba RC. Treatment of chloroquine-resistant Plasmodium falciparum infections in Vietnam. Ann Intern Med 1967;66:616-22
29. Dieckmann-Schuppert A, Franklin RM. Compounds binding to cytoskeletal proteins are active against Plasmodium falciparum in vitro. Cell Biol Int Rep 1989;13:411-18 (Pubitemid 19146853)
30. Skinner-Adams TS, Davis TM, Manning LS, Johnston WA. The efficacy of benzimidazole drugs against Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg 1997;91:580-4 (Pubitemid 27478653)
31. Lataste H, Senilh V, Wright M, et al Relationships between the structures of taxol and baccatine III derivatives and their in vitro action on the disassembly of mammalian brain and Physarum amoebal microtubules. Proc Natl Acad Sci USA 1984;81:4090-4 (Pubitemid 14054528)
32. Schrevel J, Sinou V, Grellier P, et al Interactions between docetaxel (Taxotere) and Plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci USA 1994;91:8472-6
33. Sinou V, Grellier P, Schrevel J. In vitro and in vivo inhibition of erythrocytic development of malarial parasites by docetaxel. Antimicrob Agents Chemother 1996;40:358-61 (Pubitemid 26049347)
34. Fennell BJ, Carolan S, Pettit GR, Bell A. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum. J Antimicrob Chemother 2003;51:833-41 (Pubitemid 36503416)
35. Billker O, Shaw MK, Jones IW, et al Azadirachtin disrupts formation of organised microtubule arrays during microgametogenesis of Plasmodium berghei. J Eukaryot Microbiol 2002;49:489-97 (Pubitemid 36000052)
36. Lucantoni L, Yerbanga RS, Lupidi G, et al Transmission blocking activity of a standardized neem (Azadirachta indica) seed extract on the rodent malaria parasite Plasmodium berghei in its vector Anopheles stephensi. Malar J 2010;9:66
37. Tuszynski JA, Curry SH. Compositions and methods for the treatment of malaria. US7265248; 2007
38. Zisterer D, Williams DC, Mulligan J. Microtubule Targeting Agents. WO2007088528; 2007
39. Mulligan JM, Greene LM, Cloonan S, et al Identification of tubulin as the molecular target of proapoptotic pyrrolo-1, 5-benzoxazepines. Mol Pharmacol 2006;70:60-70
40. Taraschi FT, Pouvelle B. Methods of treating plasmodium and babesia parasitic infections. US5356927; 1994
41. Taraschi FT, Pouvelle B. Methods of killing protozoal parasites. US5631278; 1997 References [40,41] show the use of taxol in killing of malaria parasite.
42. Sakowicz R, Beraud C, Guo J, Freedman R. Novel motor protein of P. falciparum and methods for its use. WO2003048320; 2003
43. Reynoldson JA, Thompson RCA, Davis TME. Benzimidazole compounds in the treatment of malaria. WO1995011675; 1995
44. Coombs GH, Muller S. Recent advances in the search for new anti-coccidial drugs. Int J Parasitol 2002;32:497-508 (Pubitemid 34273800)
45. Morrissette NS, Mitra A, Sept D, Sibley LD. Dinitroanilines bind alpha-tubulin to disrupt microtubules. Mol Biol Cell 2004;15:1960-8 (Pubitemid 38401842)
46. Greif G, Lieb F, Fedtke C. Agents for combating Neospora spec. US6753298; 2004
47. Morgan RE, Werbovetz KA. Selective lead compounds against kinetoplastid tubulin. Adv Exp Med Biol 2008;625:33-47 A review of tubulin-targeting agents for kinetoplastid parasites.
48. Uddin MJ, Smithson DC, Brown KM, et al Podophyllotoxin analogues active versus Trypanosoma brucei. Bioorg Med Chem Lett 2010;20:1787-91
49. Cavalli A, Bolognesi ML. Neglected tropical diseases: Multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J Med Chem 2009;52:7339-59
50. Chan MM, Grogl M, Chen CC, et al Herbicides to curb human parasitic infections: In vitro and in vivo effects of trifluralin on the trypanosomatid protozoans. Proc Natl Acad Sci USA 1993;90:5657-61 (Pubitemid 23176220)
51. Mitra A, Sept D. Binding and interaction of dinitroanilines with apicomplexan and kinetoplastid alpha-tubulin. J Med Chem 2006;49:5226-31 (Pubitemid 44260218)
52. Berman JD. Structure-function analysis of antimicrotubule dinitroanilines against promastigotes of the parasitic protozoan Leishmania mexicana. Antimicrob Agents Chemother 1994;38:1692-3 (Pubitemid 24203597)
53. Werbovetz KA, Sackett DL, Delfín D, et al Selective antimicrotubule activity of N1-phenyl-3,5-dinitro-N4,N4-di-npropylsulfanilamide (GB-II-5) against kinetoplastid parasites. Mol Pharmacol 2003;64:1325-33 (Pubitemid 37532222)
54. Marques C, Carvalheiro M, Pereira MA, et al Efficacy of the liposome trifluralin in the treatment of experimental canine leishmaniosis. Vet J 2008;178:133-7
55. Esteves MA, Fragiadaki I, Lopes R, et al Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents. Bioorg Med Chem 2010;18:274-81
56. Werbovetz K, Sackett DL, Salem MM. Antileishmanial dinitroaniline sulfanomides with activity against parasite tubulin. US7211696; 2007
57. Callahan H, Kelley C, Grogl M, Schuster BG. Compositions having anti-leishmanial activity. US6433023; 2002
58. Lepape P. Compounds, in particularly of urea derivatives or esters of Haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases. US20050165068A1; 2005
59. Rao PN, Mooberry SL, Cessac JW, Tinley TL. 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity. US6852710; 2005
60. Kamath K, Okouneva T, Larson G, et al 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther 2006;5:2225-33 (Pubitemid 44530459)
61. Elmendorf HG, Dawson SC, McCaffery JM. The cytoskeleton of Giardia lamblia. Int J Parasitol 2003;33:3-28 (Pubitemid 36126403)
62. Best WM, Sims CG, Thompson RCA, Reid SA. Antiparasitic compounds. WO2006108224; 2006
63. Hotez PJ, Brindley PJ, Bethony JM, et al Helminth infections: The great neglected tropical diseases. J Clin Invest 2008;118:1311-21 (Pubitemid 351500423)
64. McKellar QA, Jackson F. Veterinary anthelmintics: Old and new. Trends Parasitol 2004;20:456-61 (Pubitemid 39195054)
65. Kohler P. The biochemical basis of anthelmintic action and resistance. Int J Parasitol 2001;31:336-45 (Pubitemid 32295900)
66. Robinson MW, Trudgett A, Hoey EM, Fairweather I. The effect of the microtubule inhibitor tubulozole-C on the tegument of triclabendazole- susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol Res 2003;91:117-29 (Pubitemid 37204523)
67. Mavrova ATS, Anichina KK, Vuchev DI, et al Antihelminthic activity of some newly synthesized 5(6)-(un)substituted- 1H-benzimidazol-2- ylthioacetylpiperazine derivatives. Eur J Med Chem 2006;41:1412-20 (Pubitemid 44883392)
68. McConville M, Brennan GP, Flanagan A, et al Ultrastructural changes to the tegumental system and the gastrodermal cells in adult Fasciola hepatica following in vivo treatment with the experimental fasciolicide, compound alpha. Parasitology 2009;136:665-80
69. Marquez-Navarro A, Nogueda-Torres B, Hernandez-Campos A, et al Anthelmintic activity of benzimidazole derivatives against Toxocara canis second-stage larvae and Hymenolepis nana adults. Acta Trop 2009;109:232-5
70. Chassaing CPA. Novel benzimidazole (thio) carbamates with antiparasitic activity and the synthesis thereof. WO2007014846; 2007
71. McKellar QA, Benchaoui HA. Synergistic compositions containing benzimidazole anthelmintics and Methylenedioxyphenyl compounds. US5744494; 1998
72. Banks BJ, Dutton CJ, Goudie AC. Benzimidazole anthelmintic agents. US5459155; 1995
73. Donald GM, Wayne FL. Anthelmintic preparation. US5925374; 1999
74. Banks BJ, Dutton CJ, Goudie AC. Benzimidazole anthelmintic agents. WO1993018010; 1993
75. Banks BJ, Dutton CJ, Goudie AC. Benzimidazole anthelmintic agents. WO1993002059; 1993
76. Banks BJ, Dutton CJ, Goudie AC. Benzimidazole anthelmintic agents. WO1993010101; 1993
77. Chow DS, Gupta P, Qi Y, et al Parenteral and oral formulations of benzimidazoles. WO2010011289; 2010
78. Chow DS, Liang D. Parenteral and oral formulations of benzimidazoles. WO2005018623; 2005
79. Hennessy DR, Ashes JR, Scott TW, et al Antiparasitic compositions. WO1994027598; 1994
80. Xiang X, Plamann M. Cytoskeleton and motor proteins in filamentous fungi. Curr Opin Microbiol 2003;6:628-33 (Pubitemid 38020061)
81. Yamashita RA, May GS. Motoring along the hyphae: Molecular motors and the fungal cytoskeleton. Curr Opin Cell Biol 1998;10:74-9 (Pubitemid 28066123)
82. Shaw SL, Maddox P, Skibbens RV, et al Nuclear and spindle dynamics in budding yeast. Mol Biol Cell 1998;9:1627-31 (Pubitemid 28337511)
83. Richards KL, Anders KR, Nogales E, et al Structure-function relationships in yeast tubulins. Mol Biol Cell 2000;11:1887-903 (Pubitemid 30307920)
84. Filler SG, Sheppard DC. Fungal invasion of normally non-phagocytic host cells. PLoS Pathog 2006;2:1099-105 A review on how microtubules are involved in fungal disease mechanism. (Pubitemid 46045197)
85. Odds FC, Brown AJ, Gow NA. Antifungal agents: Mechanisms of action. Trends Microbiol 2003;11:272-9 (Pubitemid 36725017)
86. De Carli L, Larizza L. Griseofulvin. Mutat Res 1988;195:91-126 (Pubitemid 18066065)
87. Vanden Bossche H, Engelen M, Rochette F. Antifungal agents of use in animal health-chemical, biochemical and pharmacological aspects. J Vet Pharmacol Ther 2003;26:5-29 (Pubitemid 36308200)
88. Kiso T, Fujita K, Ping X, et al Screening for microtubule-disrupting antifungal agents by using a mitotic-arrest mutant of Aspergillus nidulans and novel action of phenylalanine derivatives accompanying tubulin loss. Antimicrob Agents Chemother 2004;48:1739-48 (Pubitemid 38544383)
89. Green SJ, Papathanassiu A. Use of anti-estrogenic compounds as anti-fungal agents. US6605622; 2003
90. Yue J, Yang S, Ding J, et al Pseudolaric acid-B derivatives, their preparation and pharmaceutical compositions. US6887895; 2005
91. Tong YG, Zhang XW, Geng MY, et al Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 2006;69:1226-33
92. Pettit GR, Pettit RK. Anti-cryptococcal peptides. US6620911; 2003
93. Bai RL, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 1990;265:17141-9
94. Pettit GR. Antifungal activity of the spongistatins. US5883120; 1999
95. Uckun FM, Mao C, Jan ST, et al Spongistatins as tubulin targeting agents. Curr Pharm Des 2001;7:1291-6 (Pubitemid 32798810)
96. Pettit GR, Minardi MD, Rosenberg HJ. Halocombstatins and methods of synthesis thereof. US7223747; 2007
97. Edlind TD, Cruz MC. Treatment of Cryptococcus neoformans infection. US5434163; 1995
98. Hayashi Y, Palladino MA, Grodberg J. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof. US7064201; 2006
99. Pettit GR, Pettit RK. Antifungal phenylethylene. US20050014849A1; 2005
100. Irschik H, Jansen R, Sasse F. Biologically active compounds obtainable from Sorangium Cellulosum. WO2007009897; 2007
101. Hopkins CD, Wipf P. Isolation, biology and chemistry of the disorazoles: New anti-cancer macrodiolides. Nat Prod Rep 2009;26:585-601
102. Al-awar RS, Ehlhardt WJ, Gottumukkala SV, et al Pharmaceutical compounds. WO1998008506; 1998
103. Shih C, Williams DC. Method for treating fungal infections. US6180679; 2001
104. Eggen M, Georg GI. The cryptophycins: Their synthesis and anticancer activity. Med Res Rev 2002;22:85-101 (Pubitemid 34160581)
105. Jacobs RS, Wilson L, Madari H. Coumarin compounds as microtubule stabilizing agents and therapeutic uses. US6660767; 2003
106. Page M. Carbohydrate derivatives of paclitaxel and docetaxel, method for producing same and use thereof. WO2004063211; 2004
107. Dumonteil E. Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Infect Genet Evol 2009;9:1075-82
108. Vercruysse J, Knox DP, Schetters TP, Willadsen P. Veterinary parasitic vaccines: Pitfalls and future directions. Trends Parasitol 2004;20:488-92 (Pubitemid 39195059)
109. Lubega GW, Byarugaba DK, Prichard RK. Immunization with a tubulin-rich preparation from Trypanosoma brucei confers broad protection against African trypanosomosis. Exp Parasitol 2002;102:9-22 An example of tubulin as an antigen. (Pubitemid 36279579)
110. Lubega GW, Ochola DO, Prichard RK. Trypanosoma brucei: Anti-tubulin antibodies specifically inhibit trypanosome growth in culture. Exp Parasitol 2002;102:134-42 (Pubitemid 36629186)
111. Li SQ, Fung MC, Reid SA, et al Immunization with recombinant beta-tubulin from Trypanosoma evansi induced protection against T. evansi, T. equiperdum and T. b. brucei infection in mice. Parasite Immunol 2007;29:191-9 (Pubitemid 46434885)
112. Plouffe DA, Belosevic M. Antibodies that recognize alpha- and beta-tubulin inhibit in vitro growth of the fish parasite Trypanosoma danilewskyi, Laveran and Mesnil, 1904. Dev Comp Immunol 2006;30:685-97
113. Katzenback BA, Plouffe DA, Haddad G, Belosevic M. Administration of recombinant parasite beta-tubulin to goldfish (Carassius auratus L.) confers partial protection against challenge infection with Trypanosoma danilewskyi Laveran and Mesnil, 1904. Vet Parasitol 2008;151:36-45
114. Probst P, Stromberg E, Ghalib HW, et al Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning. J Immunol 2001;166:498-505 (Pubitemid 32038469)
115. Bhowmick S, Ali N. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PLoS One 2009;4:e5820
116. Ding J, Bao W, Liu Q, et al Immunoprotection of chickens against Eimeria acervulina by recombinant alpha-tubulin protein. Parasitol Res 2008;103:1133-40
117. Kim SM, Lee EH, Kwon SR, et al Preliminary analysis of recombinant beta-tubulin of Pseudocohnilembus persalinus (Ciliophora: Scuticociliatida) as a vaccine antigen candidate against scuticociliatosis. Aquaculture 2006;260:21-6 (Pubitemid 44279789)
118. Wampande EM, Richard MJ, Lubega GW. Classical ligands interact with native and recombinant tubulin from Onchocerca volvulus with similar rank order of magnitude. Protein Expr Purif 2007;55:236-45
119. Oxberry ME, Geary TG, Winterrowd CA, Prichard RK. Individual expression of recombinant alpha- and beta-tubulin from Haemonchus contortus: Polymerization and drug effects. Protein Expr Purif 2001;21:30-9 References [116-119] show recombinant tubulin as antigen and drug target. (Pubitemid 32614493)
120. Balaban N, Waithaka HK, Njogu AR, Goldman R. Intracellular antigens (microtubule-associated protein copurified with glycosomal enzymes)- possible vaccines against trypanosomiasis. J Infect Dis 1995;172:845-50
121. Liu JY, Qiao XG, Du DY, Lee MGS. Receptor-mediated endocytosis in the procyclic form of Trypanosoma brucei. J Biol Chem 2000;275:12032-40
122. Gull K. The cell biology of parasitism in Trypanosoma brucei: Insights and drug targets from genomic approaches? Curr PharmDes 2002;8:241-56 (Pubitemid 34449881)
123. Bughio NI, Faubert GM, Prichard R. Characterization and biological activities of anti-Brugia pahangi tubulin monoclonal antibodies. Int J Parasitol 1993;23:913-24
124. Knapp E, Yusibov V. Trypanosoma antigens, vaccine compositions and related methods. WO08134643; 2008
125. Prichard RK, Lubega GW, Byarugaba DK, Ochola DOK. Vaccine against trypanosomiasis. US0165529; 2003
126. Prichard RK, Bughio NI, Faubert GN. Peptides and vaccines derived from nematode tubulin. WO9410201; 1994
127. Geary T, Prichard RK, Bughio NI, Faubert GN. Peptides of nematode tubulin and methods of use. WO9632132; 1996
128. Von Samson-Himmelstjerna G, Harder A, Schnieder T, Pape M. DNA coding beta tubulin and use thereof. WO0104281; 2001
129. Dalton JP, Andrews SJ. Vaccine containing aperoxiredoxin and/or a beta-tubulin. WO9747740; 1997 . References [124-129] exemplify use of tubulin as antigen for vaccine purpose.
130. Kang S, Hong YS. RNA interference in infectious tropical diseases. Korean J Parasitol 2008;46:1-15 Review of RNAi in parasitic protozoal and helminthic diseases.
131. Ngo H, Tschudi C, Gull K, Ullu E. Double-stranded RNA induces mRNA degradation in Trypanosoma brucei. Proc Natl Acad Sci USA 1998;95:14687-92
132. Best A, Handoko L, Schluter E, Goringer HU. In vitro synthesized small interfering RNAs elicit RNA interference in african trypanosomes: An in vitro and in vivo analysis. J Biol Chem 2005;280:20573-9 (Pubitemid 40776759)
133. Robinson KA, Beverley SM. Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania. Mol Biochem Parasitol 2003;128:217-28 (Pubitemid 36549251)
134. Dasgupta D, Adhya S, Basu MK. The effect of beta-tubulin-specific antisense oligonucleotide encapsulated in different cationic liposomes on the suppression [correction of supression] of intracellular L. donovani parasites in vitro. J Biochem 2002;132:23-7 (Pubitemid 34832266)
135. Solis CF, Santi-Rocca J, Perdomo D, et al Use of bacterially expressed dsRNA to downregulate Entamoeba histolytica gene expression. PLoS One 2009;4:e8424
136. Vayssie L, Vargas M, Weber C, Guillen N. Double-stranded RNA mediates homology-dependent gene silencing of gamma-tubulin in the human parasite Entamoeba histolytica. Mol Biochem Parasitol 2004;138:21-8 (Pubitemid 39410522)
137. Aboobaker AA, Blaxter ML. Use of RNA interference to investigate gene function in the human filarial nematode parasite Brugia malayi. Mol Biochem Parasitol 2003;129:41-51 (Pubitemid 36703221)
138. Kotze AC, Bagnall NH. RNA interference in Haemonchus contortus: Suppression of beta-tubulin gene expression in L3, L4 and adult worms in vitro. Mol Biochem Parasitol 2006;145:101-10 (Pubitemid 41691859)
139. Geldhof P, Murray L, Couthier A, et al Testing the efficacy of RNA interference in Haemonchus contortus. Int J Parasitol 2006;36:801-10 (Pubitemid 43866071)
140. Visser A, Geldhof P, de Maere V, et al Efficacy and specificity of RNA interference in larval life-stages of Ostertagia ostertagi. Parasitology 2006;133:777-83 (Pubitemid 44763973)
141. Ebhardt HA. RNA interference (RNAi) patents and human health related applications of RNAi. Rec Pat DNA Gene Seq 2007;1:128-33
142. Hoke GD, Ecker DJ. Inhibition of Candida. WO9203455; 1992 A patent on effect of tubulin gene suppression in C. albicans.
143. Sackett DL, Werbovetz KA, Morrissette NS. Isolating tubulin from nonneural sources. Methods Cell Biol 2010;95:17-32
144. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov 2009;8:69-85
145. Edelman MJ, Gandara DR, Hausner P, et al Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003;39:197-9 (Pubitemid 36173621)
146. Tevaarwerk AJ, Holen KD, Alberti DB, et al Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res 2009;15:1460-5
147. Mayer TU, Kapoor TM, Haggarty SJ, et al Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-4 Use of microscopy to identify microtubule-associated kinesin inhibitor.
148. Davis A, Martinez S, Nelson D, Middleton K. A tubulin polymerization microassay used to compare ligand efficacy. Methods Cell Biol 2010;95:331-51
149. Davis A, Middleton K. Lyophilized tubulins. US6750330; 2004
150. Morgan RE, Ahn S, Nzimiro S, et al Inhibitors of tubulin assembly identified through screening a compound library. Chem Biol Drug Des 2008;72:513-24 High-throughput tubulin polymerization-based assay to identify microtubule inhibitor of parasite and cancer.
151. Hollomon DW, Butters JA, Barker H, Hall L. Fungal beta-tubulin, expressed as a fusion protein, binds benzimidazole and phenylcarbamate fungicides. Antimicrob Agents Chemother 1998;42:2171-3 (Pubitemid 28420344)
152. Giles NL, Armson A, Reid SA. Characterization of trifluralin binding with recombinant tubulin from Trypanosoma brucei. Parasitol Res 2009;104:893-903 Reference [152] shows recombinant tubulin as drug target.
153. Palatnik-de-Sousa CB, Silva-Antunes I, Morgado Ade A, et al Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas. Vaccine 2009;27:3505-12
154. Geldhof P, De Maere V, Vercruysse J, Claerebout E. Recombinant expression systems: The obstacle to helminth vaccines? Trends Parasitol 2007;23:527-32
155. Lee P, Xuchen Z. Intranasal delivery of nucleic acid molecules. US0265927; 2005
156. Duran N, Marcato PD, Teixeira Z, et al State of the art of nanobiotechnology applications in neglected diseases. Curr Nanosci 2009;5:396-408
157. Caffrey CR, Steverding D. Recent initiatives and strategies to developing new drugs for tropical parasitic diseases. Expert Opin Drug Discov 2008;3:173-86 A review showing recent efforts for antiparasitic drug discovery. (Pubitemid 351279487)
158. Sasaki J, Ramesh R, Chada S, et al The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 2002;1:1201-9
159. Gupta K, Bishop J, Peck A, et al Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin. Biochemistry 2004;43:6645-55 (Pubitemid 38697564)
160. Panda D, Rathinasamy K, Santra MK, Wilson L. Kinetic suppression of microtubule dynamic instability by griseofulvin: Implications for its possible use in the treatment of cancer. Proc Natl Acad Sci USA 2005;102:9878-83 (Pubitemid 40993661)